Plain Language Study Results Summaries
What Are Plain Language Study Results Summaries?
Plain Language Study Results Summaries are descriptions in everyday language of the design and results of clinical studies. These summaries (also called layperson summaries, plain language summaries, lay language summaries, simple summaries, and trial results summaries) are intended to make the clinical results of these studies understandable and accessible to patients, healthcare providers, caregivers, researchers, and a general audience.
Please use the search function below to find Plain Language Study Results Summaries for Pfizer-sponsored global clinical trials. For more information about a specific study, please visit ClinicalTrials.gov on the ClinicalTrials.gov Identifier (NCT) link on the study results page.
Category & Conditions: Cancer
Study Phase : 2
Medicine: DAURISMO TABLETS(GLASDEGIB)
PrintDownloadCategory & Conditions: Skin Diseases and Conditions
Study Phase : 2
Medicine: EUCRISA™(CRISABOROLE)
PrintDownloadCategory & Conditions: Cardiovasular Diseases and Conditions
Study Phase : 2
Medicine: FRAGMIN®(DALTEPARIN SODIUM INJECTION)
PrintDownloadCategory & Conditions: Neurological Diseases and Conditions
Study Phase : 3
Medicine: LYRICA® AND LYRICA®CR(PREGABALIN) AND (PREGABALIN EXTENDED RELEASE TABLETS)
PrintDownloadCategory & Conditions: Vaccine-related Conditions
Study Phase : 3
Medicine: PREVNAR 13(PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE [DIPHTHERIA CRM197 PROTEIN])
PrintDownloadCategory & Conditions: Cardiovasular Diseases and Conditions
Study Phase : 3
Medicine: VYNDAQEL® (TAFAMIDIS MEGLUMINE) CAPSULES AND VYNDAMAX™ (TAFAMIDIS) CAPSULES
PrintDownloadCategory & Conditions: Cancer
Study Phase : 3
Medicine: Bavencio (avelumab)
PrintDownloadCategory & Conditions: Cancer
Study Phase : 1/2
Medicine: Lorbrena (lorlatinib)
PrintDownloadCategory & Conditions: Rare Diseases
Study Phase : 2
Medicine: marstacimab (PF-06741086)
PrintDownloadCategory & Conditions: Immune System Diseases and Conditions
Study Phase : 2
Medicine: PF-06480605
PrintDownloadCategory & Conditions: Vaccine-related Conditions
Study Phase : 2
Medicine: PF-06482077
PrintDownloadCategory & Conditions: Cancer
Study Phase : 2
Medicine: Talzenna (talazoparib)
PrintDownload